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Abstract
Purpose To present data from an interim analysis of a Phase II
trial designed to determine the feasibility, safety, and efficacy
of individualising treatment based on renal dosimetry, by giv-
ing as many cycles as possible within a maximum renal bio-
logically effective dose (BED).
Method Treatment was given with repeated cycles of 7.4 GBq
177Lu-DOTATATE at 8-12-week intervals. Detailed dosimetry
was performed in all patients after each cycle using a hybrid
method (SPECT + planar imaging). All patients received
treatment up to a renal BED of 27 ± 2 Gy (α/β = 2.6 Gy)
(Step 1). Selected patients were offered further treatment up
to a renal BED of 40 ± 2 Gy (Step 2). Renal function was
followed by estimation and measurement of the glomerular
filtration rate (GFR).
Results Fifty-one patients were included in the present analy-
sis. Among the patients who received treatment as planned,
the median number of cycles in Step 1 was 5 (range 3-7), and
for those who completed Step 2 it was 7 (range 5-8); 73%
were able to receive >4 cycles. Although GFR decreased in
most patients after the completion of treatment, no grade 3-4
toxicity was observed. Patients with a reduced baseline GFR
seemed to have an increased risk of GFR decline. Five patients
received treatment in Step 2, none of whom exhibited a sig-
nificant reduction in renal function.
Conclusions Individualising PRRT using renal dosimetry
seems feasible and safe and leads to an increased number of
cycles in the majority of patients. The trial will continue as
planned.
Keywords 177Lu-DOTATATE . Neuroendocrine .
Dosimetry . PRRT . Renal function
Introduction
Data from several clinical trials show peptide-receptor radionu-
clide therapy (PRRT) to be a well-tolerated and effective treat-
ment of neuroendocrine tumours (NETs) [1–8]. Although
PRRT has been used for the treatment of NETs for many years,
there is still room for optimisation in some aspects, one of them
being individualised treatment taking into account patient-
specific factors to maximise efficacy and minimise toxicity.
Dosimetry-based treatment is one way of achieving this.
The dose-limiting organs for PRRT are the bone marrow
and the kidneys, the latter being a greater problem when using
90Y-DOTATOC than with 177Lu-DOTATATE [9, 10]. One
way of optimising PRRT is to ensure that the tumour receives
as many cycles of therapy as possible within reasonable limits
for the risk organs. This individualised approach to PRRT has
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been previously evaluated by Sandstrom et al [11], demon-
strating a high variability in the number of cycles achieved
using this treatment strategy and a renal absorbed dose (AD)
limit of 23 Gy. The current protocol is based on the same
principle, but aims to explore the limits of bone marrow and
renal dose by putting the dosimetric results in relation to clin-
ical effects and using higher dose limits. This individualised
approach demands detailed dosimetry which, in the case of
177Lu-DOTATATE, can be achieved using post-therapeutic
scintigraphy, owing to its characteristic of emitting not only
the (therapeutic) β--radiation, but also γ-radiation.
There are no established dose limits for bone marrow and
kidneys for 177Lu-PRRT, so such data has to be extrapolated
from external beam radiotherapy (EBRT) and PRRTwith 90Y-
DOTATOC. Data from external bilateral kidney irradiation in-
dicate a 5% risk of renal dysfunction at 5 years (TD5/5) at a
mean AD of 18-23 Gy and 0.5-1.25 Gy/fraction [12], or at an
AD of 15-18 Gy and 2-Gy fractions [13]. The AD leading to a
50% risk of renal damage at 5 years (TD50/5) has been estimat-
ed to be 28 Gy [12, 13]. Data from EBRTcannot, however, be
directly applied to PRRT due to what can be summarised as the
intrinsic differences between external and systemic radiother-
apy: different dose rates and fractionation schemes, an inho-
mogeneous absorbed dose distribution and possibly different
radiobiological mechanisms of cytotoxicity resulting in vary-
ing biological effect, despite the same amount of energy de-
posited per unit mass. The linear-quadratic (LQ) radiobiologi-
cal model is used to convert the AD to the biologically effec-
tive dose (BED), taking into account some of these differences
[14]. Assuming that the LQ-model is valid for PRRT, the limits
extrapolated from EBRT of 18 Gy and 28 Gy would corre-
spond to BED limits of 32 Gy and 50 Gy,1 respectively.
Data from clinical trials of PRRT with 90Y-DOTATOC that
include dosimetric studies [15, 16] indicate a relationship be-
tween renal BED (estimated from pre-treatment scintigraphy or
PET) and toxicity. According to MIRD pamphlet no. 20, the
BED TD50/5 is 44 Gy (α/β = 2.5 Gy), and the threshold for
radiation nephropathy is 33 Gy [14]. These results were applied
in a prospective clinical trial [17], where 22 patients completed
treatment with repeated cycles of 90Y-DOTATOC with the aim
of not exceeding an accumulated renal BED of 37 Gy (α/β =
2.5 Gy), showing no grade 3-4 toxicity at 18-month follow-up.
When attempting to correlate outcomes to AD or BED, it is
essential to use an accurate dosimetric method together with a
precise definition of effect. So far, published data on the neph-
rotoxicity of 177Lu-PRRT have mainly been based on planar
dosimetry [18, 19], which is known to have inherent limita-
tions regarding the accuracy of activity quantification, and
renal function calculated from plasma creatinine as a surrogate
for measuring the glomerular filtration rate (GFR). Dose limits
similar to those found for EBRTand 90Y-DOTATOC have not
been determined. This may be because most patients have
received the standard of 4x7.4 GBq, which, as shown below,
in the majority of patients leads to a renal BEDwell below the
above-mentioned limits, but also because inaccurate dosime-
try and renal function estimates may obscure a relationship
between dose and toxicity.
Another difficulty encountered when studying the effect of
radiation on renal function is the co-existence of other factors
that contribute to a decline in GFR. The classic risk factors for
nephropathy (diabetes, hypertension, old age, previous neph-
rotoxic therapies or procedures) have been proposed to in-
crease the risk of renal failure post-PRRT [9]. However, in a
subsequent large meta-analysis, the predictive power of these
risk factors was questioned [20]. Also, in a recent analysis of
patients receiving a kidney dose of on average 19.3 Gy, none
of the included risk factors had a significant effect on renal
function [18]. The GFR at the start of PRRT could also affect
the risk of subsequent renal failure, as suggested by an analy-
sis of 51 patients treated with 177Lu-DOTATATE, showing
that those who had a reduced initial GFR also received a
higher renal AD/administered activity [19]. Renal insufficien-
cy is a late occurring toxicity, and a follow-up time of at least
18 months after treatment is required.
Our group has previously compared the results of different
dosimetric methods, including planar and SPECT-based
methods, to determine the renal BED after 177Lu-DOTATATE
treatment [21]. Based on our findings, and in accordance with
the indications in MIRD pamphlet no. 26 [22], we designed a
Phase II clinical trial using a hybrid planar- and SPECT-based
method to continuously evaluate the cumulative renal BED
after each cycle, which then guided the number of cycles given.
Here, we present the results of an interim analysis of this trial.
The aims of this analysis are to describe how individualised
dosimetry-based treatment planning affects the number of cy-
cles each patient receives, and to describe the development of
renal function during follow-up, to ensure an acceptable bal-
ance between the risks and benefits of therapy. It includes the
first 51 patients enrolled in the trial, of 100 patients planned.
Patients and methods
Trial design
This is an interim analysis of a Phase II, multicentre, prospec-
tive clinical trial using 177Lu-DOTATATE to treat metastatic
neuroendocrine tumours. The trial is being conducted at two
Swedish university hospitals, and has been approved by the
regional ethics review board and national regulatory authori-
ties. Further details on the protocol can be found at www.
clinicaltrials.gov (NCT01456078). All patients have given
their written informed consent to participate.
1 If not otherwise specified, an α/β value of 2.6 Gy has been used for the
BED-calculations.
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The primary objective of the trial is to study the efficacy
and safety of an individualised dosimetry-based treatment
with 177Lu-DOTATATE up to a cumulative BED to the kid-
neys of 27(±2) Gy. Secondary objectives are to study the same
aspects but in a selected group of patients without risk factors
for renal or haematological toxicity, who may receive treat-
ment up to 40(±2) Gy.
Study population
The basic eligibility criteria for inclusion are: adult patients
with histologically verified, progressive metastatic neuroen-
docrine tumour with a Ki67 index ≤20%; tumour lesions must
bemeasureable according to RECIST v1.1 and have an uptake
on somatostatin receptor scintigraphy that is higher than that
of normal liver parenchyma; WHO performance status ≤ 2;
normal liver and bone marrow function and a baseline mea-
sured GFR ≥50 mL/min/1.73 m2, determined by iohexol or
51Cr-EDTA clearance. Risk factors for nephropathy are iden-
tified at baseline (diabetes, hypertension, age > 70 years, prior
liver embolization, and prior chemotherapy).
Treatment
Each cycle of 177Lu-DOTATATE is given at a standard activ-
ity of 7.4 GBq at 8-12-week intervals. A reno-protective ami-
no acid infusion is started 30 min before and continued until
8 h after the infusion of 177Lu-DOTATATE. The number of
cycles received by each patient is determined by the accumu-
lated renal BED, evaluation of renal function, haematological
tolerance and trimestral radiological evaluations. All patients
are offered treatment up to a BED of 27(±2) Gy (Step 1), as
long as there is no progression of the disease or treatment-
limiting toxicity. Thereafter, those who have no risk factors
for haematological or renal toxicity, non-progressive disease
and good tolerance, are offered continued treatment up to a
cumulative renal BED of 40(±2) Gy (Step 2).
Post-therapy imaging and renal dosimetry
After each cycle, four whole-body anterior-posterior planar
scintigraphies are performed (at nominal times 1, 24, 48 or 96
and 168 h post-injection). At 24 h post-injection SPECT/CT
imaging and an X-ray scout are also acquired. Images are
exported in DICOM format and further processed using the
LundADose software for 2D/3D dosimetry developed at our
department. The procedure for dosimetry is further described
in supplemental data, including considerations related to the
renal pharmacokinetics. The AD and BED of left and right
kidney are calculated separately, and the mean values are deter-
mined. For calculation of BED from the time-dose rate curve, a
numerical method is used, taking into account repair of suble-
thal damage during protracted irradiation [23]. A kidneyα/β of
2.6 Gy andmonoexponential repair with a half-time of 2.8 h are
assumed, in analogy with previous publications [9].
Follow-up of renal function
Renal function is analysed at baseline by serum creatinine,
estimation of GFR (eGFR) using the MDRD formula and
the measured GFR (mGFR) determined by iohexol or 51Cr-
EDTA clearance. Renal function is monitored between cycles
using serum creatinine and eGFR before each cycle and
mGFR is determined at least once a year, after completion of
Step 1 and Step 2, and additionally according to investigator
criteria. Follow-up time is defined as time from inclusion to
point of last follow-up.
For the present analysis, the development of the median
mGFR and the annual change in eGFR (ΔeGFR) are deter-
mined. TheΔeGFR is calculated for each patient individually
by linear regression to eGFR versus time data and dividing the
obtained slope by the initial mGFR value (mGFRi).
As an exploratory analysis, the projected time to a clinical-
ly significant reduction in renal function (GFR < 30 mL/min/
1.73 m2) is also included, based on the observation that pa-
tients who experience radiation nephropathy tend to exhibit a
continued decline in renal function [12]. Thus, as an approx-
imation, the product of mGFRi andΔeGFR is calculated and
the time when the GFR reaches 30 mL/min/1.73 m2 (G3 tox-
icity) determined by extrapolation.
Results
Patient population
Inclusion of patients in the trial is ongoing, with 51 patients
having been included at the time of analysis. The results pre-
sented are in part based on all included patients (median
follow-up 18 months, range 1-43), in part based only on the
patients who had reached end of treatment (EOT) at the time
of analysis (EOTall, N = 41, median follow-up 24 months,
range 1-43). The patients are further sub-grouped into those
who terminated treatment because they had reached the
protocol-specified BED limit (EOTdose, N = 22, median
follow-up 28 months, range 13-39), or due to toxicity, adverse
event or progressive disease (EOTtox/PD, N = 15) as indicated
in the text. Treatment was ongoing in ten patients at the time of
analysis, and four were excluded from the analysis of effect
and toxicity due to protocol deviations. Five patients had re-
ceived treatment within Step 2.
The baseline characteristics for all 51 patients are presented
in Table 1. Half were women, and the median age at inclusion
was 67 years (range 35-80). The most common primary tu-
mour origins were small intestine (73%) and pancreas (10%),
the rest being evenly distributed between pulmonary,
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colorectal and unknown origins. Two thirds of the tumours
had a Ki67 index of 0-2% and the remaining one-third 3-
20%, at the time of diagnosis. The baseline mGFR (mGFRi)
median value was 71mL/min/1.73 m2 (range 48-104), and the
median eGFR 87 mL/min/1.73 m2 (range 43-159). One third
of the patients had mGFRi >80 mL/min/1.73 m2 (G0
according to NCI CTCAE v4.0), 49% G1 (60-80 mL/min/
1.73 m2), and 18% G2 (30-59 mL/min/1.73 m2). The preva-
lence of risk factors for nephropathy at baseline was as fol-
lows: none (39%), one (27%), two (25%), and more than two
(8%). Two thirds of the patients had a performance status of
ECOG 0-1, and one third had ECOG 2.
Renal dosimetry
The median AD and BED/cycle for all 51 patients were
4.5 Gy (range 2.2-14.3) and 4.9 Gy (range 2.3-19.1), respec-
tively, calculated from a total of 199 cycles. The wide range
was due to both inter- and intrapatient variability. The maxi-
mum values were attributable to a patient whowas admitted to
hospital due to intercurrent obstructive nephrolithiasis a few
days after receiving treatment. As shown in Fig. 1, the median
AD/administered activity was 0.61 Gy/GBq (range 0.3-1.98),
and the median BED/AD was 1.09 (range 1.03-1.34). The
median BED/administered activity was 0.67 Gy/GBq (range
0.3-2.6), and the median effective half-life was 51.6 h (range
38-69) (data not shown). The AD and BED of the left and
right kidneys were generally similar in the same patient and
cycle. The fractional BED deviation, calculated as the differ-
ence between the left and right kidney divided by the mean of
the left and right kidney, was on average -1.8% for individual
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Fig. 1 (a) Absorbed dose per unit administered activity (Gy/GBq)
calculated from a total of 199 cycles. Stars denote outliers. (b) BED per
absorbed dose. Stars denote the AD/BED from outliers obtained in A
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cycles and -0.2% for the whole treatment. No systematic dif-
ference in the BED of the left and right kidneys was seen,
although in the above-mentioned patient with obstructive
nephrolithiasis the BED differed for non-methodological
reasons.
Themedian interval between cycles was 77 days (range 56-
210). The median number of cycles received within Step 1 by
the EOTdose patients was five (range 3-7) reaching a mean
renal BED of 26.5 Gy (range: 22.6-32.1). The five patients
who completed treatment within Step 2 received a median of
seven cycles (range 5-8) reaching a mean renal BED of
37.3 Gy (range: 33.1-39.8). The individual results are illus-
trated in Fig. 2, where the considerable inter- and intrapatient
variability regarding the BED/cycle and the total number of
cycles is evident. As an illustrative example, we can compare
patients 111 and 112, who both received treatment up to an
accumulated BED of approximately 25 Gy, one after only
three cycles, while the other required six cycles. Conversely,
patients 015 and 016 received the same number of cycles, but
very different total kidney BEDs (36 Gy vs. 26 Gy).
In the EOTdose group 16/22 patients (73%) received more
and 2/22 (9%) received less than four cycles. As illustrated in
Fig. 3, this leaves only four patients (18%) for whom four is
the optimal number of cycles according to the BED limits
used in this protocol. If all 22 patients had received four
cycles, the mean renal BED would have been 22.7 (range
14.3-38.1) Gy (assuming the same BED in cycle 4 as in cycle
3 for the patients who only received three cycles).
Renal function vs. cumulative renal BED
In the EOTall group, data on eGFR development ≥ 6 months
from baseline were available for 32 patients (median follow-
up 19months), while follow-up data on mGFRwere available
for 22 (median follow-up 22 months). The contribution of
cumulative BED, mGFRi, and pre-existing risk factors for
nephrotoxicity was compared pair-wise (Fig. 4). Based on
the observation that the EOTtox/PD patients were overrepre-
sented in the group exhibiting a more rapid decline in GFR
(see Table 2), these were analysed separately. The patients
with the smallest GFR-loss were those with an mGFRi ≥
80 mL/min/1.73 m2, including those treated to a BED of
40(±2) Gy, and those with the largest GFR loss was the
EOTtox/PD group. All patients with a GFR loss > 10% either
hadmGFRi < 80mL/min/1.73m2 and/or risk factors for neph-
rotoxicity. The dose-limiting toxicity was haematological
(Table 2).
Renal function over time
As illustrated in Fig. 5a, median mGFR decreased with in-
creasing follow-up, although the number of patients with a
follow-up >24 months is small, making it difficult to draw
any conclusions beyond this point in time. The mean absolute
annual change in mGFRwas -4.3 mL/min/1.73 m2 (range +11

























Fig. 3 Frequency distribution of number of cycles delivered within the
protocol-specified BED-limits
Fig. 2 Cumulative BED, number of treatment cycles received and BED/cycle for the patients who completed treatment after reaching the protocol-
specified BED limit (EOTdose)
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population of a similar age range is between 0.4 ± 3.6 and 1.8
± 2.6 mL/min [24]. The loss of renal function among the
PRRT-treated patients was thus slightly more rapid, although
no grade 3-4 toxicity (i.e. GFR < 30 mL/min/1.73 m2) was
observed. As illustrated in Fig. 5b, four patients exhibited a
decrease in eGFR >30% compared to baseline, one of whom
was the patient with obstructive nephrolithiasis, two had pro-
gressive disease at the time the decrease in renal function was
confirmed, and in the fourth patient the decline in eGFR im-
proved, from -30% to -24%, with further follow-up.
Among the five patients who received treatment within
Step 2, the mean change in mGFR from baseline to the last
point of follow-up was -7% (range -14% to +5%), while the
mean change in eGFR was -14% (range -25% to +7%). Two
patients exhibited a reduction in renal function fromG0 to G1,
while G0 renal function was maintained in three patients
throughout follow-up (data not shown). The median mGFR
follow-up for this subgroup was 29 months (range 24-37).
Figure 6 shows results of the exploratory analysis of the
time when significant renal toxicity would be reached (grade
3, GFR <30 mL/min/1.73 m2). Six patients (19%) actually
showed an improvement in GFR during follow-up, five of
which had risk factors for nephrotoxicity. None had a
projected decline to GFR < 30 mL/min/1.73 m2 within 1 year,
but it was projected within 2-5 years for six patients (34%).
The projected time to GFR <30 mL/min/1.73 m2 was 6-10
years in five patients (22%) and longer than 10 years in seven
patients (25%).
Discussion
In the present trial, we have prospectively collected data on
renal function and dosimetry after 177Lu-DOTATATE
PRRT and individualised treatment based on an assumed
maximum tolerable dose to risk organs, with the aim of
maximising the AD to tumour tissue and thus the probabil-
ity of antitumor effect. When seeking to define a relation-
ship between absorbed dose and toxicity, it is essential to
have accurate measurements of both. In this trial, we used
an ambitious dosimetric method together with regular
measurement and estimation of renal function, to be able
to draw firm conclusions as the number of patients and
follow-up time increases.
A challenge when designing the trial was to define the
BED limits in a way that increased the likelihood of therapeu-
tic gain without venturing patient safety. As summarised in the
introduction, the evidence available would indicate a thresh-
old for long-term nephrotoxicity of 32-33 Gy, without taking
into account clinical risk factors. Based on Bodei et al [9] risk
factors for nephrotoxicity seemed to clearly affect the recom-
mendable BED limits. Based on this, we defined the renal
BED-limits to 27 for patients with risk factors and 40 Gy for
those without.
When the physician sees a patient after X cycles and a
cumulated renal BED of YGy, aware that the renal dose varies
from one cycle to another, he/she has to attempt to predict the
cumulative BED with additional cycles. Certain variability in
the final dose (±2 Gy) was, therefore, added as a compromise
with clinical reality. In a previous study we also investigated
the combined uncertainties in SPECT/CT-based renal dosim-
etry in 177Lu-PRRT, using the same SPECT/CT methods as
in this study, and were able to quantify one standard deviation
to 6% [25]. Currently we are performing uncertainty analyses
for the hybrid planar-SPECT method used in this trial. The
results are beyond the scope of this work and will, therefore,
be presented separately.
One may object to there being no upper dose limit for the
bone marrow (BM) in this trial. Sandstrom et al, however,
found that the BM AD/cycle was <0.2 Gy and concluded that
it was the renal AD that was dose-limiting in 98% of the
patients, even when permitting a renal AD up to 29 Gy [11].
The acute BM toxicity is monitored using blood sampling at
regular intervals during treatment. Since acute BM toxicity is
easily detected, and the limit of BM AD is yet undefined for
PRRT, we decided to study BM AD in an exploratory
substudy, the results of which will be presented separately.
For a majority of the patients the whole-body AD has been
determined (see Table 2).
A fundamental difficulty with dosimetry in PRRT is the
lack of radiobiological data regarding dose-response relation-














Fig. 4 Pair-wise comparisons of
ΔeGFR for the EOTdose group
(N = 22) and an eGFR follow-up
>6 months categorized by initial
mGFR (mL/min/1.73 m2), the
existence or not of risk factors
(Risk F) for nephrotoxicity, and
the cumulative renal BED (Gy).
The results for the EOTtox/PD
group (N = 10) are presented in
the column to the left
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suffers from considerable variability in radionuclides, dosi-
metric methods, and clinical data making pooling of results
difficult. We are obliged to extrapolate from EBRT and the
LQ-model without knowing its applicability to PRRT when
taking into account the numerous physical and biological dif-
ferences between the treatment modalities. To be able to go
forward with studies incorporating rigorous dosimetry and
clinical follow-up which may add to the knowledge base, we
inevitably have to make certain assumptions a priori based on
the best available evidence, and continuously re-evaluate the
correctness of these assumptions as results become available.
Estimation of GFR based on plasma creatinine is subject to
inaccuracies which vary depending on the method used. The
MDRD and the Cockcroft-Gault formulas are the most com-
monly used, and recent reviews support MDRD as being
somewhat more reliable [26, 27]. Superior to any estimation




















112 6 Y 21 23 1.5 94 −7.6 28 Dose
117 5 Y 21 23 N/A 66 −10.5 18 Dose
019 4 Y 22 24 1.4 71 1.0 18 Dose
105 5 Y 23 24 2.4 85 −1.6 17 Dose
110 4 Y 22 24 1.7 63 −1.3 32 Dose
111 3 Y 21 24 0.9 68 3.2 28 Dose
118 5 Y 22 24 1.7 70 −6.2 16 Dose
018 5 Y 23 25 1.9 59 11.5 20 Dose
016 6 N1 24 26 1.8 60 −16 22 Dose
108 6 Y 25 27 2.7 97 −13.2 28 Dose
003 3 N2 24 28 2.0 78 −34.2 19 Dose
011 5 Y 25 28 1.6 72 −2.1 30 Dose
115 4 Y 26 29 1.2 61 5.6 21 Dose
002 7 Y 27 30 3.0 62 −5.5 39 Dose
005 5 Y 27 30 2.0 69 −9.1 39 Dose
120 4 Y 26 30 1.5 78 −16.2 13 Dose
008 5 Y 29 32 1.6 48 −19.5 32 Dose
104 6 N 30 33 1.2 83 −4.3 29 Dose
015 6 N 32 36 2.1 82 −1.7 25 Dose
014 8 N 35 38 2.2 88 −1.5 28 Dose
007 8 N 36 39 3.9 85 −7.4 35 Dose
103 8 N 37 40 1.6 84 −0.7 37 Dose
Median 5 25 28 1.7 72 −4.9 28
B
001 4 N 18 20 1.3 87 3.4 8 PD
017 5 Y 23 25 1.8 71 −29.1 15 PD
124 3 Y 14 15 0.9 67 54 6 PD
010 2 Y 6.9 7.4 0.9 73 −7.8 7 SAE
004 2 N 9.1 9.8 N/A 57 −2.4 43 Hem tox
101 4 Y 16 18 3.5 62 −7.3 9 Hem tox
106 2 N 9.2 10 0.7 96 −27.4 24 Hem tox
107 3 N 12 12 1.8 91 −18.5 34 Hem tox
119 3 N 15 17 0.9 73 −21.8 17 Hem tox
122 2 N 8 8.6 1.0 56 −21.2 13 Hem tox
Median 3 13 14 1.0 72 −13.1 15
C
009 1 Y 3.9 4.2 0.8 54 N/A 5 Death/PD
012 1 Y 4.3 4.7 0.4 52 N/A 2 Death/PD
114 1 Y 3.8 4.2 0.6 104 N/A 1 Death3
013 5 N 34 38 3.2 56 N/A 29 Prot dev
109 4 N 26 28 N/A 53 N/A 33 Prot dev
113 6 Y 26 28 N/A 75 N/A 3 Prot dev
116 5 Y 20 21 N/A 69 N/A 9 Prot dev
102 2 Y 8.1 8.7 1.9 73 N/A 5 Hem tox
Median 2 13 15 1.25 54 N/A 4
Data are grouped according to reason for EOT: (A) EOTdose, (B) EOTtox/PD, (C) Prot dev and/or follow-up <6 months. ΔeGFR (annual eGFR-change)
was calculated as the slope of a line fitted to eGFR-versus-time data, divided by the initial mGFR. AD absorbed dose, BED biologically effective dose,
mGFR measured glomerular filtration rate, eGFR estimated glomerular filtration rate, EOT end of treatment, PD progressive disease, Prot dev protocol
deviation, Hem tox haematological toxicity, SAE serious adverse event. Footnotes 1: not eligible for step 2 due to previous chemotherapy, 2: intercurrent
obstructive nephrolithiasis, 3: cardiac arrest in the context of a sepsis.
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of GFR is its measurement, limited on the other hand by its
more invasive nature. In this trial we followed renal function
using both estimated and measured values. We used the less
invasive method (eGFR) for close follow-up of changes in
renal function, with regular mGFR measurements to calibrate
the eGFR values. Assuming that the difference between eGFR
and mGFR data is constant over time for the same patient, the
possible bias in eGFR values will not affect the rate of the
change. The percent change on the other hand depends on
the value used for normalization, for which the initial mGFR
value was used.
In our patient material renal function gradually declined
after treatment with 177Lu-DOTATATE, at a rate that seemed
slightly higher than what could be expected in a correspond-
ing normal population. The decline was moderate, with no
grade 3-4 toxicity observed so far. Patients with risk factors
for nephrotoxicity, or a moderately reduced mGFRi, seemed
at risk of a more rapid decline in renal function than their
healthier counterparts. A possible explanation is that risk fac-
tor patients have a lower number of functioning nephrons at
baseline than their no-risk factor counterparts and are, there-
fore, at greater risk of suffering a clinically significant reduc-
tion in GFR as a result of nephrotoxic therapies such as PRRT.
The patients showing the highest risk of GFR decline were
actually those who were not able to complete PRRT as
planned, due to non-renal toxicity/adverse event or progres-
sive disease. This suggests that factors other than the radiation
dose to the kidneys caused their nephropathy. Our results sup-
port the dose limit proposed in this trial for high-risk patients
(27 ± 2 Gy), while indicating that low-risk patients may well
tolerate further treatment.
The primary objective of PRRT in patients with progressive
NETs is to bring the tumour under control. Some deterioration
in renal function is acceptable, as long as it does not affect the
patients’ quality of life for the remainder of their lifetime.
Patients with radiation nephropathy tend to have a continuous
progressive decline in renal function. Although the rate of this
decline is unknown, it is valuable from the clinician’s point of
view to have some idea of the prognosis for toxic effects in
relation to the expected therapeutic effects of the treatment and
survival of the patient. For this reason we have attempted to
predict the long-term effects on renal function by extrapolat-
ing the rate of change of eGFR calculated for each patient to
give an approximate time to significant renal insufficiency,
defined as ≥G3. As for any exploratory analysis, the results
have to be interpreted with caution.
Our findings clearly show that individualising treatment
based on patient selection and detailed dosimetry results in
considerable variability in the number of cycles each patient
is able to receive within the pre-specified BED limits. Not
only does the AD/cycle vary between patients, but also be-
tween cycles in the same patient. The reason for the intra-
individual variations is presently unclear, although it may be
that blood pressure and degree of hydration, and thus renal
perfusion, varied between cycles secondarily affecting the res-
idence time in the kidney and thereby the AD. Previous au-
thors [18] have stated that the risk of nephrotoxicity after
standard PRRTwith four cycles is minimal, rendering dosim-
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Fig. 5 Development of renal function over time (EOTall). (a) Absolute
values of mGFR and median mGFR (dotted line) (b) % eGFR change




















Fig. 6 Projected time to significant reduction in GFR (<30 mL/min/
1.73 m2) in the EOTdose group, assuming a continued and constant rate
of decline in renal function
Eur J Nucl Med Mol Imaging
efficacy vs. toxicity, or if retreatment is being considered, we
maintain that dosimetry is necessary, based on the findings in
the present analysis.
Conclusions
Individualised dosimetry-based PRRT is feasible and safe,
with the BED limits used in this protocol, with the caveat of
the limited follow-up inherent to an interim analysis. The trial
will continue as planned.
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